The FDA has begun the process of removing a powerful opioid from the market over concerns of the potential for abuse. Endo Pharmaceuticals was recently informed by the agency that it would like to see Opana ER pulled from the nation’s shelves.
Citing concerns over the “public health consequences of abuse,” the agency is giving Endo Pharmaceuticals the opportunity to voluntarily remove Opana ER on its ...
continue reading...